Kinfo
CalciMedica, Inc. logo

CalciMedica, Inc.

CALCNASDAQHealthcare·US · USD
$1.23
+0.03 (+2.94%)
Prices as of November 17, 2026 · live

Price

Key statistics

Valuation
Market cap8.21M USD
Enterprise value1.47M USD
Trailing P/E0.30
Forward P/E-0.57
PEG ratio0.02
Price / sales0.00
Price / book2.04
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-80.28%
Return on equity-763.32%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-18.73M USD
Net income-15.11M USD
Diluted EPS-$4.41
Rev. growth (YoY)0.00%
Balance sheet
Total cash13.77M USD
Total debt6.90M USD
Debt / equity163.24
Current ratio4.96
Book value / share$0.61
Cash flow (TTM)
Operating cash flow-21.18M USD
Levered free cash flow-29.56M USD
Shares & price
Shares outstanding30.74M
Float3.82M
Held by institutions58.59%
Beta0.00
50-day MA$1.53
200-day MA$2.97
52-week high$7.20
52-week low$0.46
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-11-10-1.27-0.24+81.10%2026-08-11-1.45-2.25−55.17%2026-05-062.552.72+6.67%2026-03-03-2.06-3.45−67.48%
About CalciMedica, Inc.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target calcium release-activated calcium (CRAC) channels for serious inflammatory, immunologic, and cardiopulmonary diseases. The company’s lead candidate, Auxora, is an intravenous small-molecule CRAC channel inhibitor being evaluated in multiple settings, including acute pancreatitis, acute kidney injury, and other severe inflammatory conditions. CalciMedica also develops an oral CRAC channel inhibitor program aimed at chronic inflammatory and immunologic diseases. Its current work centers on drug discovery and clinical development for conditions where inflammation and direct cellular injury drive high unmet medical need. Based in La Jolla, California, CalciMedica plays a specialized role in the biotechnology market by advancing a differentiated calcium-channel inhibition platform for acute and chronic disease areas.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. A. Rachel Leheny Ph.D.
Employees
16
Headquarters
La Jolla, CA, United States

Frequently asked questions about CalciMedica, Inc.